Tumor microenvironment
Abstract
Breast tumors are routinely biopsied to assess the pathological stage of a tumor. We hypothesize that under the proper conditions, this diseased tissue could be used to predicatively gauge therapeutic response. In vivo tumor behavior is modified by its own microenvironment, including cues received by structural information of surrounding extracellular matrix, and by the chemical nature of the surrounding microenvironment. The tumor microenvironment exists in a less oxygenated state than does normal tissue; the surrounding cellular matrix in the tumor tissue is maintained under higher structural matrix tension because of either structural differences or increased interstitial fluid pressure. These microenvironmental parameters regulate cellular behavior, including the tumor cells' responsiveness to antitumor therapy. Our goal is to develop and validate a microfabricated breast cancer tissue bioreactor (BCTB) that will provide a controlled artificial tumor tissue microenvironment to maintain intact small breast cancer biopsy samples ex vivo for testing the response of an individual patient's tumor to chemotherapy or molecular targeted therapy. The objective of this project is to develop biomicroelectromechanical systems (BioMEMS) that will support the combination of the 3-D culture methodology with control over microenvironmental oxygen, acidity, and matrix rigidity to better approximate the in vivo tumor microenvironment ex vivo.
To validate maintenance of long-term drug delivery in our tissue bioreactor, we observed the inhibition of morphogenic growth of human mammary epithelial cell lines-MCF-10A and their invasive variants, cultured under 3-D conditions inside the system. The MCF10A and their variants undergo a distinct morphogenic transformation that results in the formation of hollow mammospheres. This complex process requires alterations in a variety of cellular functions including the degradation of the extracellular matrix that is regulated by matrix proteinases. For our drug delivery testing and validation experiments, we have introduced proteinase inhibitors into the system and detected inhibition of both proteinase activity and cellular morphogenesis. Currently, we are extending functionality of the bioreactor to include controlled oxygen and pH. Once the base reactor system is validated, we will determine whether drug response of a tumor biopsy sample evaluated within the BCTB predicts in vivo responsiveness by using murine models of breast cancer. We predict that a close approximation of the tumor microenvironment ex vivo will maintain an intact tumor biopsy specimen under proper disease conditions and that the corresponding biopsies' response to antitumor therapy will directly correlate to the in vivo responsiveness of that same agent against the tumor in situ. 
Future Directions

Figure 1. Principle design of the Breast Cancer Tissue Bioreactor (BCTB).
A) AutoCAD drawing of the lithographic mask for BCTB microfluidic channels. Dotted circles indicate cell culture chambers; B) Block-diagram of the typical layout for the clamped Breast Cancer TB indicating major components; C) A photo of the fully assembled Breast Cancer TB prototype with the gravity driven feeding system, passively regulated flow through the input/output manifolds, and a "Labtainer™" from HyClone as a waste containment system; D) A photo of the clamped Breast Cancer TB cartridge with a diagram illustrating set up for long term culture.
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Objectives
• Develop Breast Cancer Tissue Bioreactor (BCTB) for long-term cell culture
• Demonstrate delivery of the "drug" agents by analyzing both activity inhibition (i.e proteinase) and changes to cellular morphogenesis
• To functionalize the Breast Cancer Tissue Bioreactor (BCTB) with controlled oxygen and pH in the surrounding microenvironment. treatment can result in a high degree of adsorption of small molecules to the surface, which can lead to unpredictable changes in local chemokine concentrations. This potentially can have a pronounced effect during long-term culture or when total volumes of handled media is on the order of several μL or nL. This also may affect the actual concentration of "drugs" delivered into BCTB for treatments.
A. 
Conclusions
• BCTB Modular design: each reactor can be maintained under different flow (nutrient exchange) profile or connected to a single supply source via manifolds
• System allows for efficient delivery of a drug treatment (as confirmed by reduction of mammosphere formation by inhibiting proteinase activity)
• Mathematical model for diffusion inside cell chamber has been developed
• Oxygen and pH sensitive film for imaging of O 2 and pH distributions within the BCTB has been developed. O 2 film is compatible with standard cell culture. Its performance is unaffected by auto-fluorescence of collagen, phenol red, and gamma ray sterilization.
• Proper pH and oxygenation conditions within BCTB can be established by controlling pH of the supplied media and via oxygen diffusion through bulk PDMS.
Thin films for optical assessment pH levels within the BCTB cell chamber
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Inhibition of mammosphere formation in BCTB
MCF-10A MCF-10CA1d
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(-) P.I. confirmed by confocal microscopy of MCF-10A cell variants that were grown for 5 days within TTB and then overlaid with matrix containing fluorogenic protease activity probe (25 μg/ml DQ-gelatin in Hydrogel). Following 48 hr, protease activity was detected by an increase in fluorescence due to proteolysis of DQ-gelatin (Ex/Em 495/515 nm; Molecular Probes). Images representative of one plane of a z-stack (40x). Cell Culture: Cells were maintained in "Growth Media" (DMEM/F12, 5% Horse Serum, 0.1 mg.ml insulin, 0.5 mg/ml hydrocortisone and 20 ng/ml EGF) unless specified otherwise. Cells were plated into 8-well chamber slides ( 
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